Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyPediatric Oncology and HematologySolid TumorsProtocol groupBrain Tumors (ped.)Neuro-OncologyRadiotherapyDiseaseGliomaSubgroupH3 K27M-MutationIDH1-MutationIDH2-MutationWHO grade 1 and 2WHO Grade 2WHO grade 2 and 3WHO Grade 3ICD10C71.-MeSHAstrocytomaGliomaOligodendrogliomaOptic Nerve GliomaSequenceTMZL75/Radiation, Glioma, C1 (PID1452) -|- C2 (PID1453) -|- C3-13 (PID1454)ChemotherapyChemo-substanceDordavipronLomustineProcarbazineTemozolomideTioguaninVincristineVorasidenibChemo-substanceDordavipronLomustineProcarbazineTemozolomideTioguaninVincristineVorasidenibChemo-substanceDordavipronLomustineProcarbazineTemozolomideTioguaninVincristineVorasidenibChemo-substanceDordavipronLomustineProcarbazineTemozolomideTioguaninVincristineVorasidenibNo. Substances134 RadiotherapySupportive therapySupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronSupportive substanceAprepitantBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronNo. Substances34Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlAstheniaConstipationCOVID-19 infectionDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaGastrointestinal ToxicityHeadacheHepatotoxicityIncrease AminotransferasesInfectionsLeukopeniaLymphopeniaNeutropeniaRashSeizuresThrombocytopenia below 50 000/µl only studiesPublicationAuthorArrillaga-Romany I Ater JLBuckner JCMellinghoff IKvan den Bent MJ Wick WDiseaseDiffuses Gliom, H3 K27M-mutiert, Karnofsky-Score mindestens 60, mindestens 90 Tage nach RadiatioGliom (Oligodendrogliom oder Astrozytom) WHO Grad 2, residuelle Krankheit, oder RezidivGliome WHO-Grad 2, Erstlinie, ECOG 0-2Neu diagnostiziertes, nicht 1p/19q kodeletiertes anaplastisches Gliom WHO Grad 2 oder 3, ECOG 0-2Neu diagnostiziertes anaplastisches Gliom, Grad 3, ErstlinieProgressives oder residuelles Low-Grade Gliom bei Kindern, WHO Grad 1+ 2, Alter unter 10, ErstlinieOriginBrain Tumour Centre at Erasmus, Rotterdam, Netherlands, CATNON trial (EORTC study 26053-22054)Department of Neurology Clinic, University of Heidelberg, NOA-04Massachusetts General Hospital, Boston, MAMayo Clinic, Rochester, USAMemorial Sloan Kettering Cancer Center, New York, INDIGO trialUniversity of Texas MD Anderson Cancer Center, Houston, COG StudieProtocols in Revision 8 protocols foundDordaviprone 625, Glioma (PID3177 V1.0)Lomustine 110 / Vincristine 2 / Procarbazine 60 / Radiation, Glioma (PID1694 V1.2)Lomustine 110 / Vincristine 2 / Procarbazine 60, Glioma (PID1347 V1.3)Temozolomide 150, Glioma, cycle 2 (PID1453 V1.2)Temozolomide 200, Glioma, Cycle 3-13 (PID1454 V1.2)Temozolomide 75 / Radiation, Glioma, Cycle 1 (PID1452 V1.2)Tioguanin 30 / Procarbazine 50 / Lomustine 110 / Vincristine 1.5, Glioma (PID604 V1.1)Vorasidenib 40, Glioma (PID2819 V1.0)
